People and Business — 3/21
Industry happenings from the last month, all in one place.
People news
Elligo Health Research welcomed Vice President, Healthcare Partnerships Katie Eyestone, Chief People Officer Kathleen Fairall, and Vice President, Practice Success Vanessa Watson to its leadership team.
Worldwide Clinical Trials, Inc. announced that Gary Fishbein, MD, MPH, is its new executive medical director and medical lead for oncology, as well as that Jose L. Martinez, MD, has joined as senior medical director for oncology.
Trialbee announced the appointment of Craig Lipset as Chairman of the Trialbee Industry Advisory Board.
Deep 6 AI announced the addition of Jason Attanucci as Vice President of Life Sciences.
Firma Clinical recently commenced a Scientific Advisory Board for its clinical services, including biometrics/data. Members include Greg Campbell, PhD, Ming-Hui Chen, PhD, Ying Lu, PhD, L.J. Wei, PhD, Eugenia Henry, PhD, and Earl Webb Henry, MD.
Business news
Avance Clinical celebrated their strategic partnership with Medidata, and the accreditation of seven Medidata inhouse experts.
KCR announced the establishment of a new branch in Sydney, Australia.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
